首页 | 本学科首页   官方微博 | 高级检索  
     

千柏鼻炎片联合丙酸氟替卡松治疗过敏性鼻炎的临床研究
引用本文:韩加辉,张书嘉,董春光. 千柏鼻炎片联合丙酸氟替卡松治疗过敏性鼻炎的临床研究[J]. 现代药物与临床, 2020, 35(3): 521-524
作者姓名:韩加辉  张书嘉  董春光
作者单位:福建医科大学福总临床医学院(联勤保障部队第九〇〇医院)肝胆内科, 福建 福州 350025;福建医科大学孟超肝胆医院 肝病科, 福建 福州 350025;厦门大学附属东方医院 肝胆内科, 福建 福州 350025
基金项目:福建省社会发展引导性(重点)项目(2016Y0068)
摘    要:目的探讨千柏鼻炎片联合丙酸氟替卡松鼻喷雾剂治疗过敏性鼻炎的临床疗效。方法选取2018年7月-2019年7月在连云港市第一人民医院进行治疗的92例过敏性鼻炎患者,根据用药的差别分为对照组(46例)和治疗组(46例)。对照组给予丙酸氟替卡松鼻喷雾剂,1次/d,每鼻孔2喷,个别患者可以2次/d,每鼻孔2喷,症状控制后维持每个鼻孔1喷,1次/d;治疗组在对照组基础上口服千柏鼻炎片,4片/次,3次/d。两组均治疗8周。观察两组的临床疗效,比较两组治疗前后临床积分、血清学指标的变化情况。结果治疗后,对照组和治疗组的总有效率分别是80.43%、95.65%,两组比较差异有统计学意义(P<0.05)。经治疗,两组在喷嚏、鼻塞、流涕、鼻痒等症状积分均显著降低(P<0.05),且以治疗组显著(P<0.05)。经治疗,两组患者血清白细胞介素-4(IL-4)、测白细胞介素-6(IL-6)、测白细胞介素-17(IL-17)、细胞间黏附分子-1(ICAM-1)、嗜酸性细胞阳离子蛋白(ECP)水平均显著降低(P<0.05),且以治疗组显著(P<0.05)。结论千柏鼻炎片联合丙酸氟替卡松鼻喷雾剂治疗过敏性鼻炎具有较好的临床效果,可有效改善患者临床症状,降低机体炎症反应,具有一定的临床推广应用价值。

关 键 词:千柏鼻炎片  丙酸氟替卡松鼻喷雾剂  过敏性鼻炎  症候积分  白细胞介素-4  测白细胞介素-6  白细胞介素-17  细胞间黏附分子-1  嗜酸性细胞阳离子蛋白
收稿时间:2020-01-05

Clinical study on Qianbai Biyan Tablets combined with fluticasone propionate in treatment of allergic rhinitis
HAN Jia-hui,ZHANG Shu-ji,DONG Chun-guang. Clinical study on Qianbai Biyan Tablets combined with fluticasone propionate in treatment of allergic rhinitis[J]. Drugs & Clinic, 2020, 35(3): 521-524
Authors:HAN Jia-hui  ZHANG Shu-ji  DONG Chun-guang
Affiliation:Department of Hepatobiliary Medicine, Fuzong Clinical Medical College of Fujian Medical University, Fuzhou 350025, China;Department of Hepatology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, China;Department of Hepatobiliary Medicine, Oriental Hospital Affiliated to Xiamen University, Fuzhou 350025, China
Abstract:Objective To investigate the clinical efficacy of Qianbai Biyan Tablets combined with fluticasone propionate in treatment of allergic rhinitis. Methods 92 Patients with allergic rhinitis admitted to the First People''s Hospital of Lianyungang from July 2018 to July 2019 were divided into control group (n=46) and treatment group (n=46) according to the different medication. The control group was given Fluticasone Propionate Nasal Spray, once daily, two per nostril, individual patients can spray twice daily, two per nostril. After symptom control, maintain 1 spray per nostril, once daily. The treatment group was po administered with Qianbai Biyan Tablets on the basis of the control group, 4 tablets/time, three times daily. All patients were treated for 8 weeks. The clinical efficacy of the two groups was observed, and the changes of clinical scores and serological indexes before and after treatment were compared. Results After treatment, the effective rate of the control group was 80.43%, significantly lower than that of the treatment group (95.65%, P<0.05). After treatment, the scores of symptoms such as sneezing, nasal obstruction, runny nose and nasal itching in the two groups decreased, and the treatment group was the most significant (P<0.05). After treatment, the serum levels of IL-4, IL-6, IL-17, ICAM-1 and ECP in the two groups were all decreased, especially in the treatment group (P<0.05). Conclusion Qianbai Biyan Tablets combined with fluticasone propionate has good clinical effect in treatment of allergic rhinitis, and can effectively improve the clinical symptoms of patients, and also can reduce the body inflammatory response, which has good clinical application value.
Keywords:chronic hepatitis B|antiviral therapy|pegylated interferon alpha|hepatitis B vaccination|virological response
本文献已被 CNKI 维普 等数据库收录!
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号